Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy.
We established the combination of two tyrosine kinase inhibitors (TKIs), sorafenib and nilotinib, as the most cytotoxic. In addtion, to improve their bioavailability and reduce their metabolism, we encapsulated sorafenib and nilotinib into styrene-co-maleic acid micelles. The micelles' charge, size, and release rate were characterized. We assessed the effect of the combination on the cytotoxicity, cell cycle, apoptosis, protein expression, tumor spheroid integrity, migration, and invasion. The micelles exhibited a mean diameter of 100 nm, a neutral charge, and appeared highly stable. The micellar TKIs promoted greater cytotoxicity, decreased cell proliferation, and increased apoptosis relative to the free TKIs. In addition, the combination reduced the expression and activity of several tyrosine kinases and reduced tumor spheroid integrity and metastatic potential of CRPC cell lines more efficiently than the single treatments. The combination increased the therapeutic potential and demonstrated the relevance of a targeted combination therapy for the treatment of CRPC. In addition, the efficacy of the encapsulated drugs provides the basis for an in vivo preclinical testing.
International journal of nanomedicine. 2016 Jan 08*** epublish ***
Monica Archibald, Tara Pritchard, Hayley Nehoff, Rhonda J Rosengren, Khaled Greish, Sebastien Taurin
Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. , Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. , Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. , Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. , Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain. , Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.